UB-VV400 in Combination with Rapamycin in Relapsed or Refractory B-cell Malignancies
- Conditions
- Large B-cell Lymphoma
- Interventions
- Genetic: UB-VV400
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT06743503
A Phase III Study of Eque-cel in Subjects with Len-refractory RRMM (FUMANBA-03)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06464991
- Locations
- 🇨🇳
Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
🇨🇳Beijing GoBoard Boren Hospital, Beijing, China
🇨🇳Fu Xing Hospital, Capital Medical University, Beijing, China
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
- Conditions
- Relapsed/Refractory Multiple MyelomaPlasma Cell Leukemia
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05759793
- Locations
- 🇨🇳
Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, China
A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05698303
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05181501
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳The First People's Hospital of Changzhou, Changzhou, Jiangsu, China
A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
- Conditions
- B-cell Non-Hodgkin's Lymphoma
- Interventions
- Drug: Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 125
- Registration Number
- NCT05091541
A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 132
- Registration Number
- NCT05066646
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
🇨🇳Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
🇨🇳The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China